X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs BIOCON LTD - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS BIOCON LTD IPCA LABS/
BIOCON LTD
 
P/E (TTM) x 41.9 80.0 52.4% View Chart
P/BV x 3.2 7.5 42.7% View Chart
Dividend Yield % 0.2 0.2 97.1%  

Financials

 IPCA LABS   BIOCON LTD
EQUITY SHARE DATA
    IPCA LABS
Mar-17
BIOCON LTD
Mar-17
IPCA LABS/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs6431,162 55.3%   
Low Rs503483 104.2%   
Sales per share (Unadj.) Rs254.4194.6 130.8%  
Earnings per share (Unadj.) Rs16.134.4 46.7%  
Cash flow per share (Unadj.) Rs29.848.3 61.7%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %0.20.1 143.5%  
Book value per share (Unadj.) Rs194.6241.9 80.4%  
Shares outstanding (eoy) m126.20200.00 63.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.34.2 53.3%   
Avg P/E ratio x35.723.9 149.2%  
P/CF ratio (eoy) x19.217.0 113.0%  
Price / Book Value ratio x2.93.4 86.6%  
Dividend payout %6.22.9 214.1%   
Avg Mkt Cap Rs m72,300164,440 44.0%   
No. of employees `00013.39.2 144.1%   
Total wages/salary Rs m6,9607,470 93.2%   
Avg. sales/employee Rs Th2,413.54,213.9 57.3%   
Avg. wages/employee Rs Th523.2809.0 64.7%   
Avg. net profit/employee Rs Th152.4745.2 20.5%   
INCOME DATA
Net Sales Rs m32,10638,911 82.5%  
Other income Rs m2261,571 14.4%   
Total revenues Rs m32,33240,482 79.9%   
Gross profit Rs m4,4489,795 45.4%  
Depreciation Rs m1,7302,772 62.4%   
Interest Rs m241260 92.6%   
Profit before tax Rs m2,7038,334 32.4%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6751,616 41.8%   
Profit after tax Rs m2,0286,881 29.5%  
Gross profit margin %13.925.2 55.0%  
Effective tax rate %25.019.4 128.8%   
Net profit margin %6.317.7 35.7%  
BALANCE SHEET DATA
Current assets Rs m17,34040,477 42.8%   
Current liabilities Rs m9,55916,783 57.0%   
Net working cap to sales %24.260.9 39.8%  
Current ratio x1.82.4 75.2%  
Inventory Days Days10060 168.3%  
Debtors Days Days5783 68.6%  
Net fixed assets Rs m20,77945,073 46.1%   
Share capital Rs m2521,000 25.2%   
"Free" reserves Rs m24,49947,377 51.7%   
Net worth Rs m24,55348,377 50.8%   
Long term debt Rs m3,51721,082 16.7%   
Total assets Rs m39,59593,942 42.1%  
Interest coverage x12.233.1 37.0%   
Debt to equity ratio x0.10.4 32.9%  
Sales to assets ratio x0.80.4 195.8%   
Return on assets %5.77.6 75.4%  
Return on equity %8.314.2 58.1%  
Return on capital %10.512.6 83.2%  
Exports to sales %48.60-   
Imports to sales %14.20-   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,571NA-   
Fx inflow Rs m15,61712,988 120.2%   
Fx outflow Rs m5,8287,899 73.8%   
Net fx Rs m9,7905,089 192.4%   
CASH FLOW
From Operations Rs m2,7646,400 43.2%  
From Investments Rs m-1,432-4,985 28.7%  
From Financial Activity Rs m-1,591-1,775 89.7%  
Net Cashflow Rs m-259-473 54.7%  

Share Holding

Indian Promoters % 45.9 40.4 113.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 11.4 8.4 135.7%  
FIIs % 25.3 10.7 236.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 19.9 87.4%  
Shareholders   36,892 109,995 33.5%  
Pledged promoter(s) holding % 2.1 0.0 5,350.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 16, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS